Session Details
[P2]Poster Presentation
Thu. Mar 5, 2026 1:30 PM - 2:30 PM JST
Thu. Mar 5, 2026 4:30 AM - 5:30 AM UTC
Thu. Mar 5, 2026 4:30 AM - 5:30 AM UTC
Poster Session(1st Floor)
[P2-01]Validation of a commercially available ELISA for quantification of human protein in human tissue
*Hiroyuki Shimizu1 (1. Tanabe Pharma Corporation)
[P2-02]Improvement of Anti-Idiotype DNA Aptamers for Bioanalysis of Rituximab
*Naruma Uchidate1, Minori Kurihara1, Chiho Hirayama1, Nao Kobayashi1, Aogu Furusyo1, Kenji Kojima1, Kenichiro Todoroki1 (1. School of Pharmaceutical Sciences, University of Shizuoka)
[P2-03]Establishment and Validation of a ddPCR-Based Duplex Assay With Diploid Genome Normalization for Accurate Biodistribution: Comparison With DNA Quantity Normalization
*Haruka Inoue1, Sho Nakazono1, Sekiko Uehara1, Yurie Okawa1, Seulgi Lee1, Yukiko Arimura1, Akiko Suzuki1, Asako Uchiyama1, Hiroyuki Yamashita1 (1. Shin Nippon Biomedical Laboratories, Ltd.)
[P2-04]Patient-Centric Measurement of M-Protein Using High-Resolution Intact Mass Spectrometry
*Luca Genovesi1, Laurence Mayrand-Provencher1, Pierre Gontard1, Mirzo Kanoatov1, Gwenael Pottiez1 (1. CellCarta)
[P2-05]Ultra Fast Analysis of Anticoagulants in Plasma Using Triple Quadrupole Mass Spectrometer
*Miho Kawashima1, Taku Tsukamoto1 (1. Solutions COE, Analytical & Measuring Instruments Div., Shimadzu Corp.)
[P2-06]Biomarker Immunogenicity: Exploring method qualification of the anti-FcεR1α autoantibody.
*Matthew Lawless1, Nikki Chan1, Kruti Patel1 (1. Syneos Health)
[P2-07]Study on Immunogenicity Assessment Methods for Anti-AAV Antibodies
*Yoichi Tanaka1, Kanna Sato1, Namiko Ogawa1, Akiko Ishii1, Ruri Hanajiri-Kikura1 (1. National Institute of Health Sciences)
[P2-08]Determination of sgRNA and mRNA Sequence Identity by Low-Micro Flow Ion-Pair Reversed-Phase Chromatography and High-Resolution Tandem Mass Spectrometry
*Sergio Adrian Guazzotti1, Roxana Eggleston-Rangel1, Yuichi Sugiyama2, Shigeo Tojo2 (1. Phenomenex, Inc., 2. Phenomenex Div. of K.K. AB SCIEX)
[P2-09]Evaluation of anti-drug antibodies against therapeutic monoclonal antibodies andrelated product in Japanese patients with rheumatoid arthritis and their clinical impact
*Hiroko Shibata1, Kazuko Nishimura1, Eri Tsukagoshi2, Akiko Ishii-Watabe1, Yoshiro Saito3 (1. Devision of Biological Chemistry and Biologicals, National Institute of Health Sciences, 2. Devision of Medical Safety Science, National Institute of Health Sciences, 3. National Institute of Health Sciences)
[P2-10]Development of anti-PEG antibody assays and cut point setting using healthy human sera
*Kazuko Nishimura1, Hiroko Shibata1, Yoshiro Saito2, Akiko Ishii-Watabe1 (1. Division of Biological Chemistry and Biologicals, National Institute of Health Sciences, 2. National Institute of Health Sciences)
[P2-11]Case study of deviations from incurred sample reanalysis (ISR) and its improvements for bioanalysis of biopharmaceuticals
*Yuichi Yokoyama1, Yoshimi Inoue1, Masahito Ito1, Tetsuya Ohta1 (1. Safety Research Laboratories, Research Division, Tanabe Pharma Corporation)
[P2-12]Adsorption Evaluation in LC/MS analysis of peptide
*Daiki Fujimura1, Yusuke Osaka1 (1. Shimadzu Corporation)
[P2-13]Validation of an ultra-sensitive PCR assay for biomarker testing in NSCLC patients as Clinical Trial Assay (CTA)
*Nathalie Bernard1, Sara Diels3, Bart Tegenbos3, Dirk Goossens3, Lien Heyrman4, Jurgen Del Favero4, Magdalena Stolarek2, Sam Abujudeh, Barnaby Balmforth2 (1. Scientific Business Development, CellCarta NV, 2. Biofidelity Ltd, 3. Assay Development Team, CellCarta NV, 4. Global Operations, CellCarta NV)
[P2-14]Questionnaire on Quantitative Evaluation of Localization and Distribution via Fluorescence Imaging
*Kosuke Saito1, Yuchen Sun1, Akinobu Hamada2 (1. National Institute of Health Sciences, 2. National Cancer Center Research Institute)
[P2-15]Evaluation of Critical Reagents Impact for Sensitive Quantification of Antibody-Drug Conjugate in Human Plasma Using ECL
*Akiko Shindou1, Masashi Yoshimura1, Hiromi Okamoto1, Daisuke Nakai1 (1. Daiichi Sankyo Co., Ltd.)
[P2-16]Quality Assessment of Exosomes Using a Non-Targeting Analysis Sensor
*Yoichi Aoki1 (1. KONICAMINOLTA,INC Technology Development Headquarters)
[P2-17]A streamlined workflow for Discovery Bioanalysis – standardized sample clean up, rapid separations and robust, sensitive quantification
*Thanai Paxton1, Motoji Oshikata1, Nikunj Tanna2, Robert Plumb2 (1. Nihon Waters K.K., Japan, 2. Waters Corporation, USA)
[P2-18]Development of an LC–MS method for the simultaneous quantification of ethinylestradiol and drospirenone, components of oral contraceptives, in human plasma
Kazusa Nozaki1, *Takuma Shigeyama1, Takeru Yamaguchi1 (1. Bioanalysis Group, Sumika Chemical Analysis Service, Ltd.)
[P2-19]Introduction of Aptamer Discovery Cases Enabled by Konica Minolta, Inc.’s Unique Screening Technology
*Yuichiro Asai1, Hiroshi Negishi1, Kosaku Noba1, Chieko Masuda1, Rieko Takahashi1 (1. KONICA MINOLTA, INC., Technology Development Headquarters)
[P2-20]Systematic Evaluation of Sulfo-TAG Labeled Protein-A/G Reactivity with Immunoglobulins across Different Preclinical Species
*Derrick E Johnson1, Elisha North1, Sanofar Abdeen1, Sherri Rinker1, Mark O'Dell1, Hisanori Hara1, Ron Bowsher1 (1. B2S Life Sciences, LLC)